CLINICAL TRIALS PROFILE FOR AFAMELANOTIDE

All Clinical Trials for afamelanotide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00472901 ↗	Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)	Completed	Clinuvel Pharmaceuticals Limited		2007-05-01	The purpose of this study is to determine whether the afamelanotide (CUV1647) formulation is effective in preventing PLE episodes or reducing the severity of PLE symptoms in patients with a well documented history of the disease. The study also aims to determine whether treatment with afamelanotide (CUV1647) can reduce the use of rescue medication in this group.
NCT00829192 ↗	Phase II AK Study in Organ Transplant Patients	Unknown status	Clinuvel Pharmaceuticals Limited	Phase 2	2007-11-01	The purpose of this study is to determine whether afamelanotide (CUV1647) is effective in reducing the number of actinic keratoses and squamous cell carcinomas developing in immune compromised organ transplant recipients, who are at particularly high risk, over a 24 month test period. The number of lesions formed on the head, hands and forarms will be monitored over this 24 month test period.
NCT00859534 ↗	Phase II Solar Urticaria (SU) Pilot Study	Completed	Clinuvel Pharmaceuticals Limited	Phase 2	2008-12-01	Urticaria is one of the most common dermatological conditions with diverse clinical presentations and causes. Solar urticaria (SU) is a rare subset of physical urticaria, where symptoms are induced by direct exposure of the skin to sunlight. As little as 5 minutes of sun exposure can cause flares and whealing on exposed skin sites, accompanied by severe itching. The wavelengths of radiation causing the eruption (i.e. the action spectrum) are in the ultraviolet or visible light range. Initially described by Merklen in 1904, SU may have a very sudden and dramatic onset, and then rapidly disappear once the exposure ceases. A delayed form of SU has also been reported, although this is extremely rare. Information on the pathophysiology of SU is limited and symptoms are confined to areas of the body exposed to direct sunlight. The condition can be very distressing and severely impair the individual's ability to go outdoors and to tolerate indoor lighting. The standard therapy, i.e. oral antihistamines, is only partially effective and may provide little worthwhile relief of symptoms. This pilot study is proposed to evaluate implants containing 16mg CUV1647 as a prophylactic treatment for patients with SU. The effectiveness of CUV1647 will be assessed by determining the minimum urticarial dose before and after treatment.
NCT00979745 ↗	Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)	Completed	Clinuvel Pharmaceuticals Limited	Phase 3	2009-09-01	Afamelanotide is a man-made drug being studied for use as a preventative medication for EPP sufferers. It is a synthetically produced analogue of human alpha melanocyte stimulating hormone (alpha-MSH) and is not yet available on the market. The purpose of this study is to look at whether afamelanotide can reduce the number and severity of EPP symptoms when patients are exposed to light. This study will also look at how the drug is tolerated when taken by people with EPP. The study will involve the use of an implant, which comes in the form of a small rod (approximately 2 cm x 0.15 cm) to be administered under the skin. The implant may contain the study drug afamelanotide or a placebo (inactive medication). Over 450 subjects have been treated with afamelanotide to date with no serious safety concerns identified. For this study, afamelanotide has been formulated as a controlled release depot injection (implant). This means that the afamelanotide will be released slowly into the body over a few days. Once inserted, the implant will remain in the body after afamelanotide has been released and will slowly dissolve. This study will help to provide more information about afamelanotide. This information will be used to determine the safety and efficacy (the ability of the drug to produce an effect) of this drug in EPP sufferers. Up to 70 people will participate in this study from study sites across Europe.

Clinical Trial Conditions for afamelanotide

Condition Name

Condition Name for afamelanotide
Intervention	Trials
Erythropoietic Protoporphyria	6
Vitiligo	5
Xeroderma Pigmentosum	2
Polymorphic Light Eruption	1

Condition MeSH

Condition MeSH for afamelanotide
Intervention	Trials
Protoporphyria, Erythropoietic	6
Vitiligo	5
Xeroderma Pigmentosum	2
Exanthema	2

Clinical Trial Locations for afamelanotide

Trials by Country

Trials by Country for afamelanotide
Location	Trials
United States	17
Australia	5
United Kingdom	5
Germany	3
Netherlands	3

Trials by US State

Trials by US State for afamelanotide
Location	Trials
New York	3
California	3
Michigan	2
Utah	2
Texas	2

Clinical Trial Progress for afamelanotide

Clinical Trial Phase

Clinical Trial Phase for afamelanotide
Clinical Trial Phase	Trials
PHASE1	1
Phase 3	6
Phase 2	12

Clinical Trial Status

Clinical Trial Status for afamelanotide
Clinical Trial Phase	Trials
Completed	15
Recruiting	6
Not yet recruiting	1

Clinical Trial Sponsors for afamelanotide

Sponsor Name

Sponsor Name for afamelanotide
Sponsor	Trials
Clinuvel Pharmaceuticals Limited	16
Clinuvel Europe Limited	3
Clinuvel, Inc.	2

Sponsor Type

Sponsor Type for afamelanotide
Sponsor	Trials
Industry	23

Afamelanotide Market Analysis and Financial Projection

Last updated: May 4, 2026

AFAMELANOTIDE: Clinical Trial Update, Market Analysis, and Projection

What is afamelanotide’s current clinical development status?

Afamelanotide (brand: Scenesse; melanocortin-1 receptor agonist) is approved in the EU and other markets for erythropoietic protoporphyria (EPP) to reduce phototoxicity. Clinical trial activity since approval has been dominated by (1) EPP program extensions and (2) evaluation in other phototoxicity and pigment-related indications.

Key clinical trial record (EPP and investigational uses)

Program/Indication	Sponsor/Developer	Trial phase / status (latest public view)	Population	Primary endpoints (typical)	What to watch next
EPP (approved use)	Clinuvel	Post-approval clinical work and registries (public updates)	EPP patients	Phototoxicity events, time-to-first event, skin photosensitivity outcomes	Expansion of dosing cadence, durability of response, and evidence packages used for payer and label maintenance
Other pigmentation or phototoxicity settings	Clinuvel (historically) / partners	Ongoing or recently completed research in public databases	Mixed cohorts depending on indication	Clinical photo-related endpoints and skin response metrics	Whether any non-EPP indication reaches phase-2 proof-of-concept and unlocks incremental commercial value
Safety and exposure characterization	Clinuvel	Ongoing pharmacovigilance and exposure-response work	EPP patients	Adverse events, tolerability, treatment adherence	Long-run safety monitoring that impacts retention and reimbursement

Sources used for clinical development context: FDA and EMA product/regulatory records, and the public clinical trial registry record for afamelanotide (EudraCT and ClinicalTrials.gov listings). [1], [2]

What do the latest registries and regulatory records imply about near-term pipeline risk?

Afamelanotide’s near-term clinical and regulatory risk profile is shaped by the fact that it is already commercial and label-focused. The highest risk is not manufacturing or acute toxicity but incremental evidence adequacy for payer reimbursement and any label expansion.

Risk drivers by category

Category	What tends to move the stock and payer narrative	Risk level
Clinical evidence	Continuation of real-world and on-label outcomes to support reimbursement	Moderate
Label and geography	Any expansion depends on evidence acceptability and local standards for EPP care	Moderate
Competitive substitution	Other photoprotection and dermatology approaches can pressure uptake	Moderate-to-high
Long-term safety	Dose frequency and chronicity; monitoring for pigment-related and systemic events	Moderate

Regulatory anchor: Scenesse is an approved melanocortin agonist for EPP to reduce phototoxicity; regulatory status is documented across EMA and FDA materials. [1], [2]

---

How big is afamelanotide’s addressable market (EPP) and where is growth likely to come from?

Afamelanotide’s market is anchored to erythropoietic protoporphyria (EPP). Commercial opportunity is driven by (1) diagnosis density, (2) guideline adoption, (3) payer coverage, and (4) treatment persistence across phototoxicity seasons.

Market definition

• Primary market: EPP patients eligible for photoprotection.
• Geographic emphasis: Europe and other jurisdictions where Scenesse is approved and reimbursed (access varies by country).
• Customer: Dermatology and rare-disease centers; reimbursement typically rare-disease pathways.

Commercial adoption mechanics

Adoption lever	Impact on net sales	Typical gating factor
Diagnosis rate	More eligible patients	Screening and specialist referral
Treatment initiation	Higher share of EPP patients on therapy	Prescriber familiarity and payer approval
Treatment persistence	Revenue durability	Seasonal dosing behavior and out-of-pocket structures
Reimbursement coverage	Reduced friction for initiation	Evidence requirements and health technology assessment outcomes

Competition and substitution risk

Afamelanotide competes within rare-disease photoprotection and dermatology pathways where other measures exist (avoidance strategies and symptom management). The key competitive metric is whether alternative therapies reduce phototoxic events with comparable tolerability and clinical convenience.

Market anchor sources for regulatory and indication framing: EMA/FDA labeling and product documentation. [1], [2]

---

What is the commercial outlook for afamelanotide: base, bull, and bear projections?

No complete public dataset is consistently available in this thread to support a fully disclosed financial forecast down to annual units and pricing by geography. What can be projected with business-grade rigor is a scenario framework anchored to adoption and persistence levers.

Scenario model (adoption-driven)

Assumptions are expressed in terms of uptake and persistence rather than specific revenue numbers.

Base case (most likely path)

• Uptake grows with EPP diagnosis and ongoing guideline familiarity.
• Persistence remains stable as dosing is seasonal and centered on phototoxic risk.
• Net effect: modest growth with occasional reimbursement or reimbursement-coverage swings.

Bull case

• Faster diagnosis capture in high-access countries.
• Improved payer coverage and narrower prior authorization barriers.
• Possible label reinforcement via supportive registry data and stronger real-world evidence.
• Net effect: higher-than-market growth with stronger retention.

Bear case

• Payer pushback or delayed reimbursement in key markets.
• Competitive substitution increases among photoprotection options.
• Net effect: slower penetration and more churn around coverage windows.

Unit and share drivers (what moves the model)

Driver	Base	Bull	Bear
Patient starts (annual)	Low-to-mid single-digit growth	High single-digit growth	Flat to low growth
Treatment persistence	Stable	Improves with evidence and payer fit	Declines with access constraints
Pricing/net revenue per patient	Stable to slight pressure	Stable or improved	Downward pressure

Commercial anchor sources: approval indication and status context from EMA and FDA materials. [1], [2]

---

What clinical and commercial milestones matter most over the next 12 to 36 months?

The most value-relevant milestones for afamelanotide are not “first-in-human” type events; they are evidence and access events that determine payer comfort and continued uptake.

Near-term milestones checklist

1. EPP real-world evidence updates that demonstrate reductions in phototoxic events and tolerability.
2. Reimbursement outcomes by geography (coverage decisions, formulary placement, utilization management).
3. Any phase-2/phase-3 proof in additional indications that uses melanocortin pathway effects to expand beyond EPP.
4. Long-term safety monitoring that affects prescriber confidence and persistence.

Registry and regulatory sources: FDA and EMA records and public trial registry listings. [1], [2]

---

Key takeaways

• Afamelanotide’s development posture is grounded in an approved EPP indication, with clinical activity largely oriented to evidence reinforcement and potential incremental expansions. [1], [2]
• Market growth is adoption-driven: diagnosis density, payer access, initiation, and persistence across phototoxic seasons. These levers dominate near-term commercial outcomes more than pipeline “phase jumps.”
• The projection range is best managed through base/bull/bear scenarios tied to patient starts and persistence, not headline revenue assumptions.
• The highest-impact milestones are reimbursement decisions, real-world outcome updates in EPP, and any non-EPP clinical proof that can justify label expansion.

---

FAQs

1) Is afamelanotide approved for erythropoietic protoporphyria?

Yes. Afamelanotide (Scenesse) is approved for EPP to reduce phototoxicity in patients with EPP. [1], [2]

2) What is afamelanotide’s primary commercial market?

Erythropoietic protoporphyria (EPP), with addressable value tied to diagnosed and treated EPP patients across approved and reimbursed geographies. [1], [2]

3) What drives afamelanotide revenue most: price or uptake?

Uptake and persistence dominate in rare disease: patient starts tied to diagnosis and payer access, and treatment continuity through phototoxic seasons. [1], [2]

4) What does the clinical pipeline likely focus on after approval?

Post-approval evidence strengthening in EPP and evaluation of related indications where melanocortin pathway signaling can translate into photoprotection or pigment-related outcomes. [1], [2]

5) What is the main risk to growth?

Reimbursement friction, access variability across geographies, and competitive substitution within photoprotection and dermatology treatment pathways. [1], [2]

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). FDA labels and related regulatory documents for Scenesse (afamelanotide). https://www.accessdata.fda.gov/
[2] European Medicines Agency. (n.d.). Scenesse (afamelanotide) product information and regulatory documents. https://www.ema.europa.eu/